Assessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosis

References

• Holland N, Wiesel P, Cavallo P, et al. Adherence to disease-modifying therapy in multiple sclerosis: Part II. Rehabil Nurs: Official J Assoc Rehabil Nurs 2001;26:221-6
   Google Scholar
• Jelinek GA, Hassed CS. Managing multiple sclerosis in primary care: are we forgetting something? Qual Primary Care 2009;17:55-61
   PubMedGoogle Scholar
• Portaccio E, Amato MP. Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs 2009;23:453-62
   PubMed Web of Science ®Google Scholar
• Smrtka J, Caon C, Saunders C, et al. Enhancing adherence through education. J Neurosci Nurs: J Am Assoc Neurosci Nurs 2010;42(5 Suppl):S19-29
   Google Scholar
• Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv 2009;6:995-1002
   PubMed Web of Science ®Google Scholar
• Alexander BM, Wechsler D, Braun TM, et al. Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 2005;63:1191-6
   Google Scholar
• Hancock LM, Bruce JM, Lynch SG. Exacerbation history is associated with medication and appointment adherence in MS. J Behav Med 2011;34:330-8
   Google Scholar
• Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008;10:225
   PubMedGoogle Scholar
• Turner AP, Williams RM, Sloan AP, et al. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil Psychol 2009;54:116-21
   PubMed Web of Science ®Google Scholar
• Wicks P, Massagli M, Kulkarni A, et al. Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ). J Med Internet Res 2011;13:e12
   Google Scholar
• Verdun di Cantogno E, Russell S, Snow T. Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices. Patient Prefer Adherence 2011;5:173-80
   PubMed Web of Science ®Google Scholar
• Yamout BI, Dahdaleh M, Al Jumah MA, et al. Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory Group. Int J Neurosci 2010;120:273-9
   PubMed Web of Science ®Google Scholar
• Brandes DW, Callender T, Lathi E, et al. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin 2009;25:77-92
   PubMed Web of Science ®Google Scholar
• Sidorenko TV, Khachanova NV, Boiko AN. [A wide support of patients with multiple sclerosis promotes success of long-term therapy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova/Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiat. 2006;256(4):568-76
   Google Scholar
• Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568-76
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
   PubMed Web of Science ®Google Scholar
• Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009;25:2303-10
   PubMed Web of Science ®Google Scholar
• Ross AP. Tolerability, adherence, and patient outcomes. Neurology 2008;71(24 Suppl 3):S21-3
   Google Scholar
• Arroyo E, Gonzalez M, Grau C, et al. [Proposals to improve adherence to immunomodulatory therapies in patients with multiple sclerosis]. Neurologia (Barcelona, Spain) 2010;25(9):544-51
   Google Scholar
• Saunders C, Caon C, Smrtka J, et al. Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis. J Neurosci Nurs: J Am Assoc Neuroscie Nurs 2010;42(5 Suppl):S10-18
   Google Scholar
• Girouard N, Theoret G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. CJNN 2008;30:18-25
   Google Scholar
• Gleason PP, Starner CI, Gunderson BW, et al. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. JMCP 2009;15:648-58
   PubMed Web of Science ®Google Scholar
• Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine: Ann Behav Med 2001;23:125-32
   PubMed Web of Science ®Google Scholar
• Tarrants M, Oleen-Burkey M, Castelli-Haley J, et al. The impact of comorbid depression on adherence to therapy for multiple sclerosis. MS Int 2011;2011(27132):1-10
   Google Scholar
• Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-3
   PubMed Web of Science ®Google Scholar
• Hutchinson M. Treatment adherence: what is the best that can be achieved? Int MS J/MS Forum 2005;12:73
   Google Scholar
• Turner AP, Kivlahan DR, Sloan AP, et al. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Multiple Sclerosis 2007;13:1146-52
   PubMed Web of Science ®Google Scholar
• Wagner EH, Austin BT, Davis C, et al. Improving chronic illness care: translating evidence into action. Health Affairs 2001;20:64-78
   PubMed Web of Science ®Google Scholar
• Hatzakis MJ Jr, Allen C, Haselkorn M, et al. Use of medical informatics for management of multiple sclerosis using a chronic-care model. J Rehabil Res Dev 2006;43:1-16
   PubMedGoogle Scholar
• IBM Statistics for Windows.Version 20.0 [computer program]. Armonk, NY: IBM Corp, 2011
   Google Scholar
• Wagner EH, Austin BT, Von Korff M. Improving outcomes in chronic illness. Manag Care Quart 1996;4:12-25
   PubMedGoogle Scholar
• Kleinman NL, Beren IA, Rajagopalan K, et al. Medication adherence with disease modifying treatments for multiple sclerosis among US employees. J Med Econ 2010;13:633-40
   PubMedGoogle Scholar